Quantum Biopharma (NASDAQ:QNTM) Posts Quarterly Earnings Results, Misses Expectations By $0.49 EPS

Quantum Biopharma (NASDAQ:QNTM) announced its quarterly earnings data on Thursday. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49), Zacks reports.

Quantum Biopharma Stock Performance

Quantum Biopharma stock traded up $0.28 during midday trading on Friday, reaching $4.11. The stock had a trading volume of 82,851 shares, compared to its average volume of 228,698. The stock’s 50-day simple moving average is $4.01 and its 200 day simple moving average is $8.91. Quantum Biopharma has a twelve month low of $2.07 and a twelve month high of $38.25. The stock has a market capitalization of $15.68 million, a PE ratio of -0.38 and a beta of 0.32.

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC acquired a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned approximately 0.27% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wall Street Zen downgraded Quantum Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.